M. Abreu, M. A. Egea, A. Calpena, M. Espina, Maria L. García
{"title":"Pioglitazone Loaded-PLGA-PEG Nanoparticles: Drug Release and Interactions","authors":"M. Abreu, M. A. Egea, A. Calpena, M. Espina, Maria L. García","doi":"10.11159/NDDTE16.106","DOIUrl":null,"url":null,"abstract":"Extended Abstract Introduction The main obstacle to transport drugs to the brain, for neurodegenerative diseases treatment, is the blood-brain barrier (BBB), acting as an immune and metabolic barrier [1]. Pioglitazone (PGZ) is an oral anti-diabetic from thiazolidinediones, agonist of the peroxisome proliferator-activated receptors (PPARs), which could play an important role on mechanisms of neurodegenerative diseases [2, 3]. The main goal of this work was the PGZ association nanostructured systems, to nanoparticles (NPs) from poly (D,L-lactide-co-glycolide) poly(ethylene glycol) (PLGA-PEG) that are able to pass BBB.","PeriodicalId":31009,"journal":{"name":"RAN","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RAN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11159/NDDTE16.106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Extended Abstract Introduction The main obstacle to transport drugs to the brain, for neurodegenerative diseases treatment, is the blood-brain barrier (BBB), acting as an immune and metabolic barrier [1]. Pioglitazone (PGZ) is an oral anti-diabetic from thiazolidinediones, agonist of the peroxisome proliferator-activated receptors (PPARs), which could play an important role on mechanisms of neurodegenerative diseases [2, 3]. The main goal of this work was the PGZ association nanostructured systems, to nanoparticles (NPs) from poly (D,L-lactide-co-glycolide) poly(ethylene glycol) (PLGA-PEG) that are able to pass BBB.
在神经退行性疾病的治疗中，将药物输送到大脑的主要障碍是血脑屏障(BBB)，它是一种免疫和代谢屏障[1]。吡格列酮(PGZ)是噻唑烷二酮类口服抗糖尿病药物，是过氧化物酶体增殖物激活受体(ppar)的激动剂，在神经退行性疾病的机制中发挥重要作用[2,3]。这项工作的主要目标是PGZ结合纳米结构系统，从聚(D, l -丙交酯-共乙二醇酯)聚(乙二醇)(PLGA-PEG)到能够通过血脑屏障的纳米颗粒(NPs)。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
